Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00624559 · ClinicalTrials.gov registry record · Phase 4
The Role of COX-2 Inhibition in Salt Sensitivity of Blood Pressure
A Phase 4 study of Hypertension, sponsored by University of Delaware.
- Completed
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT00624559 is a Phase 4 study of Hypertension that has completed, run by University of Delaware. The registered enrollment target is 12 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00624559, a Phase 4 study of Hypertension, has completed, sponsored by University of Delaware.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if the drug Celebrex changes the way the kidney gets rid of salt and maintains blood pressure.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG celecoxib (Celebrex)
Study Locations (1)
Delaware
- University of Delaware - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2008-02 |
| Est. Completion | 2009-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00624559
The ClinicalTrials.gov registry entry for NCT00624559 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (100% lower). The listed sponsor is University of Delaware, which has 106 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00624559 reports 1 study location spanning 1 distinct geographic area - top geographies include Delaware.
Frequently Asked Questions
What is clinical trial NCT00624559 about?
NCT00624559 is a clinical study titled "The Role of COX-2 Inhibition in Salt Sensitivity of Blood Pressure". The purpose of this study is to determine if the drug Celebrex changes the way the kidney gets rid of salt and maintains blood pressure.
What is the current status of trial NCT00624559?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2008-02. Estimated completion is 2009-01.
What conditions does trial NCT00624559 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT00624559?
The interventions under investigation include: Placebo (OTHER), celecoxib (Celebrex) (DRUG).
Who is sponsoring clinical trial NCT00624559?
This trial is sponsored by University of Delaware, which has 106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00624559 being conducted?
This trial has 1 study location across Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment With Aspirin After Preeclampsia: TAP Trial
RECRUITING · Phase 4
-
Impact GLP-1 Agonists Following Bariatric
RECRUITING · Phase 4
-
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
RECRUITING · Phase 4
-
Bridging the Evidence-to-practice Gap
RECRUITING · Phase 4
-
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
RECRUITING · Phase 4
-
Secondhand Tobacco Smoke and Cardiovascular Disease
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.